Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer

References

• Urmancheeva AF, Kutusheva GF, Ulrich EA. Ovarian tumors (symptoms, diagnostics and treatment). Saint-Petersburg: Publishing House N-L; 2012; p. 68. (in Russian).
   Google Scholar
• Zhu Y, Hanna N, Boutros C, Alexander HR Jr.. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol. 2013;4(1):62–71.
   PubMedGoogle Scholar
• Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–5.
   PubMed Web of Science ®Google Scholar
• Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–7.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
   PubMed Web of Science ®Google Scholar
• Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macrì A, et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 2011;37(1):4–9.
   PubMed Web of Science ®Google Scholar
• Belyaev AM, Bagnenko SF, Ruchlyada NV. Intraperitoneal chemotherapy of malignant tumors of the abdominal cavity. Saint-Petersburg: ELBI-SPb; 2007; p. 254. (in Russian).
   Google Scholar
• González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2(2):68–75.
   PubMed Web of Science ®Google Scholar
• Stukov AN, Gershanovich ML, Blank MA, et al. Antitumor drugs. Saint-Petersburg: NIKA; 2011; p. 656. (in Russian).
   Google Scholar
• Gershanovich ML, Filov VA, Cotova DG, Stukov AN, Sokolov IuN, Ivin BA. Results of phase II clinical study of antitumor drug dioxadet. Vopr Onkol. 1998;44(2):216–20, (in Russian).
   PubMedGoogle Scholar
• Pogosyanz EE, Prigozhina EL, Egolina NA. Transplanted ascitic rat ovarian tumor. Vopr Onkol. 1962;8(11):29–36, (in Russian).
   Google Scholar
• Beliaeva OA, Bespalov VG, Senchik KIu, Kireeva GS, Stukov AN, Aristova VA, et al. Experimental technology of chemoperfusion treatment of peritoneal carcinomatosis from ovarian cancer. Vopr Onkol. 2014;60(1):71–8, (in Russian).
   PubMedGoogle Scholar
• Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010;1:87–93.
   PubMedGoogle Scholar
• Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999;15:79–107.
   PubMed Web of Science ®Google Scholar
• Bespalov VG, Beliaeva OA, Kireeva GS, Senchik KIu, Stukov AN, Aristova VA, et al. Antitumor activity of dioxadet in intraperitoneal chemoperfusion treatment of advanced ovarian cancer: experimental study. Vopr Onkol. 2014;60(2):76–80.
   Google Scholar
• Bespalov VG, Belyaeva OA, Kireeva GS, Senchik KY, Stukov AN, Belyaev AM. Intraperitoneal chemoperfusion treatment of advanced ovarian cancer with dioxadet compared to cisplatin in experimental settings. Sib J Oncol. 2014;62(1):14–8, (in Russian).
   Google Scholar
• Ahmed K, Zaidi SF. Treating cancer with heat: hyperthermia as promising strategy to enhance apoptosis. J Pak Med Assoc. 2013;63:504–8.
   PubMed Web of Science ®Google Scholar
• Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12:1423–32.
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, Falcone A. Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol. 2008;134:1143–9.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68(2):301–7.
   PubMed Web of Science ®Google Scholar
• Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:143–7.
   PubMed Web of Science ®Google Scholar
• Reich G, Mapara MY, Reichardt P. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001;27:525–9.
   PubMed Web of Science ®Google Scholar
• Straka C, Oduncu F, Hinke A, Einsele H, Drexler E, Schnabel B, et al. Responsiveness to G-CSF before leucopenia predicts defense to infection in high-dose chemotherapy recipients. Blood. 2004;104:1989–94.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, et al. Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents. 2006;20:29–35.
   PubMed Web of Science ®Google Scholar
• Tavares-Murta BM, Murta EFC. Systemic leukocyte alterations in cancer and their relation to prognosis. Open Cancer J. 2008;2:53–8.
   Google Scholar
• Benson AB 3rd, Read TR, Goebel SL, Koeller JM, Tormey DC. Correlations between leukocyte count and absolute granulocyte count in patients receiving cancer chemotherapy. Cancer. 1985;56:1350–5.
   PubMed Web of Science ®Google Scholar
• Michael M, Goldstein D, Clarke SJ, Milner AD, Beale P, Friedlander M, et al. Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer. 2006;6:297–304.
   PubMed Web of Science ®Google Scholar
• Tavares-Murta BM, Mendonca MA, Duarte NL. Systemic leukocyte alterations are associated with invasive uterine cervical cancer. Int J Gynecol Cancer. 2010;20:1154–9.
   PubMed Web of Science ®Google Scholar